Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05212337 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

FITMI - First In Treating Male Infertility

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 282 to confirmed 180
    • Primary completion date changed from estimate of Dec 30, 2024 to Oct 22, 2024
    • Site details revised
    v4
  2. Study description expanded, about 60 wordsv3
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This RCT aims to assess whether treatment with Denosumab can improve semen quality in infertile men selected by serum AMH as a positive predictive biomarker.
Trial Details
NCT Number NCT05212337
Lead Sponsor Martin Blomberg Jensen
Conditions
(from sponsor)		 Infertility, Male
Related terms Infertility, Male
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov